Gene-editing therapies are regulated in the United States by FDA's Center for Biologics Evaluation and Research as human gene therapy products, reviewed through the Investigational New Drug pathway under 21 CFR 312.23.
RNA therapeutics are drugs whose active substance is nucleic acid — small interfering RNA, antisense oligonucleotides, or messenger RNA — acting on the instructions a cell reads rather than blocking a finished protein.
Population genomics is the large-scale application of genomic technologies to study populations of individuals, a definition maintained by the National Human Genome Research Institute.
Genomic data privacy in the United States rests on a patchwork: the Genetic Information Nondiscrimination Act of 2008 bars the use of genetic information in health insurance and employment decisions, while NIH policy governs federally funded research data.
Genetic testing oversight in the United States has returned to its pre-2024 framework: on September 19, 2025, the FDA reverted 21 CFR 809.3(a) to its prior text, after a federal district court vacated the 2024 laboratory-developed-test rule on March 31, 2025, per the FDA’s policy page.
The FDA has cleared GenEditBio's investigational new drug application for GEB-101, an in vivo genome-editing therapy for TGFBI corneal dystrophy, the company announced on January 5, 2026.